Buy Immatics on the Financing Floor; a Levered Play on TCR Clinical Momentum
Immatics is trading near a financing-induced floor after a December 2025 $10 underwritten offering and is showing multiple positive clinical readouts across its TCR-T and TCER pipelines. This trade idea treats today's price as a de-risked entry into a high-upside clinical-stage oncology story: conservative near-term upside to low double-digits and …